Solstice rises with $225M to develop next-gen CTLA-4 drug from China

Phase 2Positive

AI Analysis

Summary

Solstice Oncology emerged from stealth with $225M in funding to develop a next-generation CTLA-4 antibody acquired from Harbour BioMed, having secured FDA IND approval for a Phase 2 trial.

Clinical Trial Data

Phase

Phase 2

Outcome Details

IND application approved by FDA for Phase 2 trial

Importance:6/10

Sentiment:

0.70

Solstice OncologyCTLA-4OncologyIND ApprovedFundingHarbour BioMed

Related Companies

$DFPH $CHHE

Read the original article

Published by BioSpace on September 9, 2026 11:01 AM

Read Original